Abstract
BackgroundA simple, robust, precise, and an accurate HPLC method was established for simultaneous estimation of xylometazoline hydrochloride and ipratropium bromide from a nasal spray dosage form. The effective separation was obtained by injecting 10 μl of sample and standard solutions on to an Inertsil ODS column, 250 × 4.6, mm, 5 μ at 45 °C using phosphate buffer with 1-pentane sulphonic acid sodium salt at pH 4.7 as a mobile phase A and acetonitrile as the mobile phase B. The gradient was optimized with a flow rate of 1 mL/min and a wavelength of 210.0 nm.ResultThe complete analytical method validation was successfully carried out as per ICH guidelines. The retrieval study was carried out at 50% to 150% level of working concentration, and results were in the range of 99 to 101% for both the analytes. The linearity was proven from 4 to 150% of working concentration with linear regression curve (R2=0.999) for both the analytes. The developed method was robust for different parameters like column temperature, flow rate, mobile phase pH, composition, and gradient.ConclusionThe developed HPLC method can be successfully used for the estimation of xylometazoline hydrochloride and ipratropium bromide from nasal spray dosage form as a release test in QC department of manufacturing units.
Highlights
A simple, robust, precise, and an accurate HPLC method was established for simultaneous estimation of xylometazoline hydrochloride and ipratropium bromide from a nasal spray dosage form
The developed HPLC method can be successfully used for the estimation of xylometazoline hydrochloride and ipratropium bromide from nasal spray dosage form as a release test in QC department of manufacturing units
We have successfully developed a Reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of xylometazoline hydrochloride and ipratropium bromide from a nasal spray dosage form
Summary
A simple, robust, precise, and an accurate HPLC method was established for simultaneous estimation of xylometazoline hydrochloride and ipratropium bromide from a nasal spray dosage form. (IB) is (1R, 3R, 5S,8R)-3-[(3-hydroxy-2-phenyl propanoyl) oxy]-8-methyl-8-(propane-2-yl)-8-azabicyclo [3.2.1] octane-8-ium bromide. It is freely soluble in water and methanol, sparingly soluble in ethanol, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons. Ipratropium bromide is a bronchodilator that works via blockade of muscarinic cholinergic receptors and is clinically used in combination with other inhalation solutions or suspensions for enhanced treatment efficacy [3]. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic [4,5,6]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have